Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Government Administration Activities

HemiClor
Regional

FDA Approves Low-Dose Hypertension Treatment HemiClor

May 12, 2025May 12, 2025 - by Timothy Alexander

WEST CONSHOHOCKEN, PA — The U.S. Food and Drug Administration (FDA) has approved HemiClor, a 12.5 mg chlorthalidone tablet developed by PRM Pharma, LLC, for the treatment of hypertension in …

FDA Approves Low-Dose Hypertension Treatment HemiClor Read More

Multicolored abstract painting
National

FDA Approves Three New Natural Color Additives, Advances Initiative to Remove Petroleum-Based Dyes

May 12, 2025May 10, 2025 - by Maryann Pugh

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved three new color additives derived from natural sources, marking a significant development in the effort to phase out …

FDA Approves Three New Natural Color Additives, Advances Initiative to Remove Petroleum-Based Dyes Read More
FDA
National

FDA Tightens Oversight with Expanded Unannounced Inspections at Foreign Manufacturing Facilities

May 11, 2025May 10, 2025 - by Maryann Pugh

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has announced its plan to increase the use of unannounced inspections at foreign facilities producing foods, essential medicines, and medical …

FDA Tightens Oversight with Expanded Unannounced Inspections at Foreign Manufacturing Facilities Read More

Teleflex Incorporated
Medical Products

Teleflex Announces FDA Clearance for Expanded Use of QuikClot Control+ Hemostatic Device

May 4, 2025May 3, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the Indications for Use of its QuikClot Control+™ Hemostatic …

Teleflex Announces FDA Clearance for Expanded Use of QuikClot Control+ Hemostatic Device Read More
Johnson & Johnson
Regional

FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis

May 2, 2025April 30, 2025 - by Timothy Alexander

SPRING HOUSE, PA — On Wednesday, the U.S. Food and Drug Administration (FDA) granted approval for IMAAVY™ (nipocalimab-aahu), Johnson & Johnson’s cutting-edge FcRn-blocking antibody treatment for generalized myasthenia gravis (gMG). …

FDA Approves Johnson & Johnson’s IMAAVY for Generalized Myasthenia Gravis Read More

Orchestra BioMed Holdings
Regional

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment

May 1, 2025April 30, 2025 - by Timothy Alexander

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial, a pivotal clinical study designed to evaluate its next-generation …

Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment Read More
PA CareerLink Lancaster County
Pennsylvania

Pennsylvania Launches Initiative to Provide On-the-Spot Birth Certificates

April 30, 2025April 29, 2025 - by Maryann Pugh

LANCASTER, PA — The Pennsylvania Departments of Labor & Industry (L&I) and Health (DOH) have introduced a new initiative allowing residents to receive on-the-spot birth certificates at PA CareerLink® locations. …

Pennsylvania Launches Initiative to Provide On-the-Spot Birth Certificates Read More

U.S. Department of Agriculture
National / Social Services

USDA Tightens SNAP Eligibility Verification to Align with Executive Order 14218

April 27, 2025April 26, 2025 - by Maryann Pugh

WASHINGTON, D.C. — The U.S. Department of Agriculture (USDA) has introduced new measures to strengthen the verification of identity and immigration status for Supplemental Nutrition Assistance Program (SNAP) applicants. The …

USDA Tightens SNAP Eligibility Verification to Align with Executive Order 14218 Read More
Orchestra BioMed Holdings
Regional

Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy

April 23, 2025April 22, 2025 - by Timothy Alexander

NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that its atrioventricular interval modulation (AVIM) therapy has received Breakthrough Device Designation (BDD) from the U.S. Food and Drug …

Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy Read More
Aclaris Therapeutics
Products and Services

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial

April 23, 2025April 22, 2025 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ATI-052, a bispecific …

Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial Read More

Posts pagination

Previous 1 … 9 10 11 … 17 Next

Trending News

  • Trump Moves to Flood Market With Beef as Prices Hit Record Highs

  • State Charges Hatfield Man With Sharing Child Abuse Images, 57 Felonies Filed

  • Gunpoint Carjacking at Wilmington Shopping Center Leads to Dover Arrest

  • Teen Arrested After Gunfire Erupts at Wawa Parking Lot, Cars Hit by Bullets

  • Death Probe, Human Trafficking Arrests Mark Busy Wyomissing Police Stretch

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Alex Asunción

State Charges Hatfield Man With Sharing Child Abuse Images, 57 Felonies Filed

4 hours ago10 hours ago

Rashawn Chappell

Gunpoint Carjacking at Wilmington Shopping Center Leads to Dover Arrest

4 hours ago10 hours ago

Arrested

Teen Arrested After Gunfire Erupts at Wawa Parking Lot, Cars Hit by Bullets

4 hours ago10 hours ago

Copyright © 2026 MyChesCo.